ERBB2 and triple-negative breast carcinoma: Thus, the clinical subtypes are classified according to protein expression, as determined by immunohistochemistry (IHC), as hormone receptor positive (ER and/or PR positive), HER2 positive, or triple-negative breast cancer (ER, PR, and HER2 negative).